Folgen
Harry Anastos
Harry Anastos
Bestätigte E-Mail-Adresse bei mssm.edu
Titel
Zitiert von
Zitiert von
Jahr
Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study
AR Rastinehad, H Anastos, E Wajswol, JS Winoker, JP Sfakianos, ...
Proceedings of the National Academy of Sciences 116 (37), 18590-18596, 2019
7002019
Avoiding unnecessary magnetic resonance imaging (MRI) and biopsies: negative and positive predictive value of MRI according to prostate-specific antigen density, 4Kscore and …
UG Falagario, A Martini, E Wajswol, PJ Treacy, P Ratnani, I Jambor, ...
European urology oncology 3 (5), 700-704, 2020
872020
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers
JP Sfakianos, J Daza, Y Hu, H Anastos, G Bryant, R Bareja, KK Badani, ...
Nature communications 11 (1), 2540, 2020
422020
A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion‐guided biopsy: assessing the impact of inter‐reader variability on …
E Wajswol, JS Winoker, H Anastos, U Falagario, K Okhawere, A Martini, ...
BJU international 125 (4), 531-540, 2020
312020
Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database
K Attalla, DJ Paulucci, K Blum, H Anastos, KA Moses, KK Badani, ...
Urologic Oncology: Seminars and Original Investigations 36 (1), 14. e17-14. e24, 2018
282018
Predicting Complications Following Robot-Assisted Partial Nephrectomy with the ACS NSQIP® Universal Surgical Risk Calculator
JS Winoker, DJ Paulucci, H Anastos, N Waingankar, R Abaza, DD Eun, ...
The Journal of Urology 198 (4), 803-809, 2017
242017
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
F Audenet, AM Farkas, H Anastos, MD Galsky, N Bhardwaj, JP Sfakianos
World journal of urology 36, 1741-1748, 2018
182018
Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma
A Kaldany, DJ Paulucci, M Kannappan, AT Beksac, H Anastos, ...
Urologic Oncology: Seminars and Original Investigations 37 (10), 727-734, 2019
152019
Tim-3 and TIGIT mark Natural Killer cells susceptible to effector dysfunction in human bladder cancer
AM Farkas, F Audenet, H Anastos, M Galsky, J Sfakianos, N Bhardwaj
The Journal of Immunology 200 (1_Supplement), 124.14-124.14, 2018
132018
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer
K Attalla, AM Farkas, H Anastos, F Audenet, MD Galsky, N Bhardwaj, ...
Urologic Oncology: Seminars and Original Investigations 40 (9), 403-406, 2022
112022
Cell death under epithelial–mesenchymal transition control in prostate cancer therapeutic response
D Begemann, H Anastos, N Kyprianou
International Journal of Urology 25 (4), 318-326, 2018
92018
Displacement of lower pole stones during retrograde intrarenal surgery improves stone-free status: a prospective randomized controlled trial
AJ Yaghoubian, H Anastos, JA Khusid, R Shimonov, DJ Lundon, R Khargi, ...
The Journal of Urology 209 (5), 963-970, 2023
72023
Black race may be associated with worse overall survival in renal cell carcinoma patients
H Anastos, A Martini, N Waingankar, DJ Paulucci, AT Beksac, J Daza, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 938. e9-938 …, 2020
62020
Targeted ablative therapies for prostate cancer
JS Winoker, H Anastos, AR Rastinehad
Genitourinary Cancers, 15-53, 2018
62018
Sientific program of 36th World Congress of endourology Programm Book
M Takhar, M Alshalalfa, A Gupta, S Prasad
J. Endourol 32, P1-A573, 2018
32018
Reverse trendelenburg positioning minimizes stone retropulsion during ureteroscopic laser lithotripsy: a prospective randomized study
H Anastos, AJ Yaghoubian, JA Khusid, RA Chandhoke, DJ Lundon, ...
Journal of Endourology 37 (6), 660-666, 2023
22023
Tim-3 and TIGIT mark NK and T cells susceptible to effector dysfunction in human bladder cancer
AM Farkas, F Audenet, H Anastos, WK Oh, MD Galsky, JP Sfakianos, ...
Cancer Research 78 (13_Supplement), 4745-4745, 2018
22018
V4-02 GOLD NANO-PARTICLE DIRECTED FOCAL LASER ABLATION FOR PROSTATE TUMORS USING US AND MR FUSION TECHNOLOGY
JS Winoker, PA Shukla, MA Carrick, H Anastos, CJ Knauer, AK Tewari, ...
The Journal of Urology 197 (4S), e375-e376, 2017
22017
PD26-08 IMPACT OF REVERSE TRENDELENBURG POSITION ON URETERAL STONE RETROPULSION: A PROSPECTIVE RANDOMIZED STUDY
J Khusid, H Anastos, R Chandhoke, D Lundon, A Sadiq, J Bamberger, ...
The Journal of Urology 206 (Supplement 3), e440-e440, 2021
12021
PD65-04 MR/US FUSION GUIDED ULTRA-FOCAL GOLD NANOPARTICLE DIRECTED LASER ABLATION OF PROSTATE TUMORS: RESULTS IN THE FIRST 11 PATIENTS (PHASE I/II TRIAL)
H Anastos, J Winoker, P Shukla, S Cumarasamy, J Sfakianos, M Carrick, ...
The Journal of Urology 199 (4S), e1226-e1226, 2018
12018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20